An Optimal Protocol to Analyze the Rat Spinal Cord Proteome

Biomarker Insights

Volumn 4, Issue , 2009, Pages

  Gil Dones, F ^a   Alonso Orgaz, S ^a   Avila, G ^a   Martin Rojas, T ^a   Moral Darde, V ^a   Barroso, G ^a   Vivanco, F ^b,c   Scott Taylor, J ^a   Barderas, M G ^a  

^a Hospital Nacional de Parapléjicos   (United States)

^b Department of Immunology ^*  (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Liquid Chromatography Mass Spectrometry Mass Spectrometry (LC MS MS); proteome; proteomics; spinal cord; two dimensional electrophoresis (2 DE)

Indexed keywords

EID: 85127040906     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMI.S2965     Document Type: Article

References (52)

1. Bonita R. Epidemiology of Stroke. Lancet. 1992; 339: 342–4.
2. Alonso I., Regidor E., Rodriguez C., Gutierrez-Fisac J.L. The main causes of death in Spain. Med Clin (Bare). 1996; 12: 441–5.
3. Beattie M.S., Hermann G.E., Rogers R.C., Bresnahan J.C. Cell death in models of spinal cord injury. Prog Brain Res. 2002; 137: 37–47.
4. Profyris C., Cheema S.S., Zang D., Azari M.F., Boyle K., Petratos S. Degenerative and regenerative mechanisms governing spinal cord injury. Neurobiol Dis. 2004; 3: 415–36.
5. Sindrup S.H., Jensen T.S. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain. 1999; 83: 389–400.
6. Hansson P.T., Dickenson A.H. Pharmacological treatment of peripheral neuropathic pain conditions based on shared commonalities despite multiple etiologies. Pain. 2005; 113: 251–4.
7. Chen H., Lamer T.J., Rho R.H. et al. Contemporary management of neuropathic pain for the primary care physician. Mayo Clin Proc. 2004; 79: 1533–45.
8. Lanzrein A.S., Johnston C.M., Perry V.H. et al. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis Assoc Disord. 1998 Sep; 12(3): 215–27.
9. Berger Rachel Pardes, Pierce Mary Clyde, Stephen R., Wisniewski et al. Neuron-Specific Enolase and S100B in Cerebrospinal Fluid After Severe Traumatic Brain Injury in Infants and Children. Pediatrics. 2002 Feb 2; 109(1): e31.
10. Brown P., Kenney K., Little B. et al. Gajdusek. Intracerebral distribution of infectious amyloid protein in spongiform encephalopathy. Annals of Neurology. 38(2): 245–53.
11. Allan Butterfield D. Debra Boyd-Kimball and Alessandra Castegna. Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration. Journal of Neurochemistry. 2003; 86: 1313–27.
12. Puchadesa Maja, Hanssona Sara Folkesson, Carol L. et al. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Molecular Brain Research. 2003 Oct 21; 118(1-2): 140–6.
13. Kunz S., Tegeder I., Coste O. et al. Comparative proteomic analysis of the rat spinal cord in inflammatory and neuropathic pain models. Neuroscience Letters. 2005; 381: 289–93.
14. Ding Q., Wu Z., Guo Y. et al. Proteome analysis of up-regulated proteins in the rat spinal cord induced by transection injury. Proteomics. 2006; 6: 505–18.
15. Yan X., Liu T., Yang S. et al. Proteomic profiling of the insoluble pellets of the transected rat spinal cord. J Neurotrauma. 2009; 26: 179–93.
16. Li Ka Wan, Martin P., Hornshaw Roel C., Van der Schors et al. Proteomics Analysis of Rat Brain Postsynaptic Density. Implications of the Diverse Protein Functional Groups for the Integration Ofsynaptic Physiology. Journal of Biological Chemistry. 2004 Jan 9; 279: (2): 987–1002.
17. Fountoulakis Michael, Kossida Sophia. Proteomics-driven progress in neurodegeneration research. Electrophoresis. 2006; 27: 1556–73.
18. Orth A.P., Batalov S., Perrone M., Chanda S.K. The promise of genomics to identify novel therapeutic targets. Expert Opin Ther Targets. 2004; 8: 587–96.
19. Choudhary J., Grant S.G. Proteomics in postgenomic neuroscience: the end of the beginning. Nat Neurosci. 2004; 7: 440–5.
20. Bermudez-Crespo J., Lopez J.L. A better understanding of molecular mechanisms underlying human diseases. Proteomics Clin Appl. 2007; 1: 983–1003.
21. Pandey A., Mann M. Proteomics to study genes and genomes. Nature. 2000; 405: 837–46.
22. Norin M., Sundstrom M. Structural proteomics: Developments in structure-to-function predictions. Trends Biotechnol. 2002; 20: 79–84.
23. Matsumoto H., Komori N. Protein identification on two-dimensional gels archived nearly two decades ago by in-gel digestion and matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Anal Biochem. 1999; 270: 176–9.
24. Weston A.D., Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res. 2004; 3: 179–96.
25. van der Greef J., Stroobant P., van der Heijden R. The role of analytical sciences in medical systems biology. Curr Opin Chem Biol. 2004; 8: 559–65.
26. Ideker I. Systems biology 101—what you need to know. Nat Biotechnol. 2004; 22: 473–5.
27. Marko-Varga G., Fehniger T.E. Proteomics and disease—the challenges for technology and discovery. J Proteome Res. 2004; 3: 167–78.
28. Domon B., Broder S. Implications of new proteomics strategies for biology and medicine. J Proteome Res. 2004; 3: 253–60.
29. Fernie A.R., Trethewey R.N., Krotzky A.J., Willmitzer L. Metabolite profiling: from diagnostics to systems biology. Nat Rev Mol Cell Biol. 2004; 5: 763–9.
30. Gorg A., Weiss W., Dunn M.J. Current two-dimensional electrophoresis technology for proteomics. Proteomics. 2004; 4: 3665–85.
31. O'Farrell P.H. High resolution two-dimensional electrophoresis of proteins. J Biol Chem. 1975; 250: 4007–21.
32. Carrette O., Burkhard P.R., Sanchez J.C., Hochstrasser D.F. State-of-the-art two-dimensional gel electrophoresis: a key tool of proteomics research. Nat Protoc. 2006; 1: 812–23.
33. Rosenfeld J., Capdevielle J., Guillemot J.C., Ferrara P. In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis. Anal Biochem. 1992; 203: 173–9.
34. Barderas M.G., Wigdorovitz A., Merelo F. et al. Serodiagnosis of African swine fever using the recombinant protein p30 expressed in insect larvae. Journal Virological Methods. 2000; 89: 129–36.
35. Gonzalez-Barderas M., Gallego-Delgado J., Mas S. et al. Isolation of circulating human monocytes with high purity for proteomic analysis. Proteomics. 2004; 4: 432–7.
36. Durán M.C., Mas S., Martin-Ventura J.L. et al. Proteomic analysis of human vessels: application to atherosclerotic plaques. Proteomics. 2003; 3: 973–8.
37. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72: 248–54.
38. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227: 680–5.
39. Shevchenko A., Tomas H., Havlis J., Olsen J.V., Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc. 2006; 1: 2856–60.
40. Barderas M.G., Tunon J., Darde V.M. et al. Circulating human monocytes in the acute coronary syndrome express a characteristic proteomic profile. J Proteome Res. 2007; 6(2): 876–6.
41. Nieto-Sampedro M. Neurite outgrowth inhibitors in gliotic tissue. Adv Exp Med Biol. 1999; 468: 207–24.
42. Koda M., Nishio Y., Hashimoto M. et al. Up-regulation of macrophage migration-inhibitory factor expression after compression-induced spinal cord injury in rats. Acta Neuropathol. 2004; 108: 31–6.
43. Giger R.J., Venkatesh K., Chivatakarn O. et al. Mechanisms of CNS myelin inhibition: evidence for distinct and neuronal cell type specific receptor systems. Restor Neurol Neurosci. 2008; 26: 97–115.
44. Jacobsson G., Piehl F., Meister B. VAMP-1 and VAMP-2 gene expression in rat spinal motoneurones: differential regulation after neuronal injury. Eur J Neurosci. 1998; 10: 301–16.
45. Wu G.J., Chen W.F., Sung C.S. et al. Preventive effects of intrathecal methylprednisolone administration on spinal cord ischemia in rats: the role of excitatory amins acid metabolizing systems. Neuroscience. 2007; 147: 294–303.
46. Cao F., Yang X.F., Liu W.G. et al. Elevation of neuron-specific enolase and S-100beta protein level in experimental acute spinal cord injury. J Clin Neurosci. 2008; 15: 541–4.
47. Wu X., Yoo S., Wrathall J.R. Real-time quantitative PCR analysis of temporal-spatial alterations in gene expression after spinal cord contusion. J Neurochem. 2005; 93: 943–52.
48. Kang S.K., So H.H., Moon Y.S., Kim C.H. Proteomic analysis of injured spinal cord tissue proteins using 2-DE and MALDI-TOF MS. Proteomics. 2006; 6: 2797–812.
49. Shen A., Liu Y., Zhao J. et al. Temporal-spatial expressions of p27kip1 and its phosphorylation on Serine-10 after acute spinal cord injury in adult rat: Implications for post-traumatic glial proliferation. Neurochem Int. 2008; 52: 1266–75.
50. Li G.L., Farooque M., Holtz A., Olsson Y. Expression of the ubiquitin carboxyl-terminal hydrolase PGP 9.5 in axons following spinal cord compression trauma. An immunohistochemical study in the rat. APMIS. 1997; 105: 384–90.
51. Willis D., Li K.W., Zheng J.Q. et al. Differential transport and local translation of cytoskeletal, injury-response, and neurodegeneration protein mRNAs in axons. J Neurosci. 2005; 25: 778–91.
52. Li J.Y., Henning Jensen P., Dahlström A. Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS. Neuroscience. 2002; 113: 463–78.